Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | CCNC | P24863 | 4/20 | 0.44 |
| ▸ | CDK8 | P49336 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6687513 | 0.85 | NPSR1 (0.52) | NPSR1ALDH1A1KMT2AHPGDMAPT | |
| SCHEMBL29968692 | 0.85 | NPSR1 (0.52) | NPSR1ALDH1A1KMT2AHPGDMAPT | |
| SCHEMBL6696478 | 0.85 | ALDH1A1 (0.49) | ALDH1A1KMT2AHPGDMAPTKDM4E | |
| SCHEMBL6703117 | 0.81 | MAPT (0.47) | ALDH1A1KMT2AHPGDMAPTKDM4E | |
| SCHEMBL6694739 | 0.81 | KMT2A (0.49) | ALDH1A1KMT2AHPGDMAPTKDM4E | |
| SCHEMBL6701730 | 0.81 | KMT2A (0.48) | ALDH1A1KMT2AHPGDMAPTKDM4E | |
| SCHEMBL6700560 | 0.80 | TP53 (0.60) | NPSR1ALDH1A1KMT2AHPGDMAPT | |
| SCHEMBL6805390 | 0.80 | ALDH1A1 (0.49) | ALDH1A1KMT2AHPGDMAPTKDM4E | |
| SCHEMBL6698658 | 0.78 | KMT2A (0.50) | ALDH1A1KMT2AHPGDMAPTKDM4E | |
| SCHEMBL6701774 | 0.77 | KDM4E (0.47) | ALDH1A1KMT2AHPGDMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040235855-A1 | Phospholipase C inhibitors for use in treating inflammatory disorders | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-11-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235855-A1 | Phospholipase C inhibitors for use in treating inflammatory disorders | PLA2G4C, PLA2G4B, PLA2G5 | NPSR1 891/4885ALDH1A1 1583/4885KMT2A 4455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.